no binding by TBPA (9) (10) (11) (12) (13) (14) (15) (16) . About 99%o of T3 in normal serum is in the bound form in in vitro measurements (17) . The in vitro uptake of T3 by red cells or resin, which has become a valuable test for thyroid disorders, is another evidence of the in vitro binding of T3 by the plasma proteins. It is evident that the erythrocyte uptake of T3-"31I is unphysiological in respect to lack of blood flow, the presence of an anticoagulant, and the rise of blood pH even after a short period of standing. The strong avidity of the T4-TBG interaction has previously been emphasized (18, 19) , whereas that of T3 for TBG has been variously estimated as being one-third that of T4 (19) and fifteen times weaker than T4 (20) . It is of interest that T3 and T4 have equal biological potency in the chicken; this has been ascribed to the lack of TBG in this species (21) .
The interaction between T4 and the thyroxinebinding proteins (TBP) can be demonstrated in vitro by electrophoresis and in vivo by turnover rate determinations, respectively. Agreement between in vitro and in vivo results has been shown before and after the binding capacity of TBG (22) and of TBPA (23) has been altered by drug therapy. Little has been done, however, to determine by in vivo studies whether T3 circulates bound mostly to TBG, as suggested by in vitro techniques. Furthermore, it has not been previously ascertained whether changes of the binding capacity of TBG are accompanied by concomitant variations of the rate of disappearance of T3 from the blood.
The purpose of the present study is to assess the effect of alterations of the TBG binding capacity on the acute disappearance of T3 and T4 from the circulation within 50 minutes of injection 1290 of tracer amounts of the labeled hormone. This early phase of hormone disappearance has previously been studied (24, 25) and has been chosen since it precedes the phase of significant cellular metabolism. Alterations in the binding capacity of TBG have been shown to profoundly affect this phase of T4 disappearance from the circulation (25) . The subjects studied included a control group of euthyroid persons, patients with thyroid and liver disease, patients given either estrogens or DPH, and a patient with idiopathic lack of TBG. The current results are correlated with in vitro observations of electrophoretic binding and of the T3 resin uptake test in serum from the same patients.
Methods
The euthyroid group consisted of healthy volunteers from hospital personnel and a few hospitalized patients without thyroid or liver disease or abnormalities of plasma proteins. An additional group was composed of four treated hypothyroid patients who were taking 180 mg of desiccated thyroid daily after radioactive iodine treatment for hyperthyroidism. In the untreated myxedematous group there were six patients; one suffered severe pituitary myxedema and five had idiopathic myxedema. The hyperthyroid group comprised patients with Graves' disease or toxic nodular goiter demonstrated by clinical and biochemical findings, as well as by thyroid scanning.
In the liver disease group there was one patient with serum hepatitis during the icteric phase. The rest were patients with advanced alcoholic cirrhosis and hepatic failure.
In the estrogen-treated group, all but five patients were on estrogen therapy for carcinoma of the prostate; the five noncarcinomatous subjects were also euthyroid.
The daily dosage of estrogen and duration of therapy are summarized in Table III. All patients on DPH therapy were epileptic; the dosage of the drug was 300 to 400 mg daily by mouth. An additional dose of 500 mg of DPH was injected intravenously during the 50 minutes in which the study was performed. No side effects were observed by the use of this intravenous dose of DPH.
In addition, a single patient with idiopathic lack of TBG was studied who had no clinical evidence of thyroid dysfunction; he had a low serum protein-bound iodine (PBI) and normal radioactive iodine uptake (see Table  V ).
In several patients acute disappearance studies with both T3 and TX, were carried out.
Techniques of counting. The acute half-time of disappearance of the injected radioactivity was determined by serial counting; for convenience the Radicoil apparatus was employed (24) to equalize the volumes counted.
An amount equal to 0.3 /Ac per kg of body weight of 'Ilabeled T3 or '31I-labeled T4 solution was injected intravenously; this dose contained approximately 1 gg of carrier T3 or T4. Samples containing 4 ml of blood were withdrawn in oxalated tubes 10 minutes after injection and thereafter every 5 minutes from 20 to 60 minutes. The Radicoil was filled with each sample and counted for 10 minutes in a well-type scintillation detector.
The standard was prepared in the following manner: A dose of tracer equal to that injected into the patient was added to 10 ml of plasma, allowed to stand for 30 minutes, and made up to 1,000 ml with water. It was then stirred with a magnet for 5 minutes. The same Radicoil used for the patient was filled with this mixture and counted for 10 minutes.
In vitro methods. The thyroxine binding capacity of TBG was determined by the method of Ingbar (26) . To each sample of serum was added a tracer dose of radioactive T4 (2 juc per ml, 4 /kg per 100 ml). These samples were enriched with stable L-T4 in varied concentrations for determinations of thyroxine binding capacity. The percentage distribution of labeled L-T3 among the binding proteins was similarly determined in samples of serum from the same patients; these sera were enriched with labeled T3 (2 /Ac per ml, 4 ,lg per 100 ml). The electrophoresis was performed in a Durrum cell with Whatman 3 filter paper in Tris-maleate buffer, pH 8.6, and allowed to run about 18 hours at 120 v. After drying, the strips were counted in a radioactive scanner (Nuclear-Chicago) and the areas of radioactivity calculated by planimetry. This was followed by radioautography and staining of the strips.
Free thyroxine was measured by the method of Ingbar, Braverman, Dawber, and Lee (17); the same technique was utilized to measure free Ts.
The T3 resin uptake test was performed with the Triosorb technique.'
Computation of results. Acute half-time of disappearance of labeled Ts (Ts acute half-time) and labeled T4 (T4 acute half-time) was determined by plotting the net counts per minute on semilogarithmic paper. The portion of the curve between 20 and 50 minutes was extrapolated back to zero time, and the half-time of disappearance of radioactivity was derived therefrom. The reasons for using this part of the regression curve have been discussed elsewhere (24, 25) . Briefly, this period follows the initial phase of mixing, may be analyzed as a straight line, and precedes the phase of significant cellular metabolism. The disappearance of the radioactivity from the circulation has also been expressed as a percentage of the injected dose (standard) remaining in the blood at 20 and 50 minutes after the intravenous injection of the tracer. In addition, the decline of the blood radioactivity during this 30-minute interval has been expressed Untreated myxedema (Table Ic) The mean T3 acute half-time for this group was 69.3 minutes, and the percentage of the 20-minute count remaining at 50 minutes was 73.6. Both figures are not significantly different from the result of euthyroid subjects. The results of the patient with pituitary myxedema were consistent with the results of the remaining patients with primary myxedema. However, the normal acute disappearance of T3 in the myxedematous patients was markedly different from the delayed acute appearance of T4 observed in similar patients (24, 25) .
Hyperthyroid (Table Id) The mean T3 acute half-time for this group was 81.8 minutes; this was slightly but not significantly greater than control values. The percentage of the 20-minute count remaining at 50 minutes was 77.3, also not significantly different from normal values. Patients with Graves' disease and toxic nodular goiter were included in the same group, since there was no appreciable difference in the results obtained in these two types of hyperthyroidism.
Liver disease (Table Ie) The mean T3 acute half-time was 66.9 minutes, showing no significant difference from euthyroid control values; the percentage of the 20-minute count at 50 minutes was 72.9. One patient (P.W.) had acute serum hepatitis; the results obtained did not differ from the remainder of the group. The other patients were all suffering from advanced alcoholic cirrhosis and liver failure.
Estrogen-treated (Table III) In vitro. There was a consistent increase in the T4 binding capacity of TBG in all patients studied, with a mean of 50.4 ,ug per 100 ml of plasma [findings similar to those previously reported in pregnancy (5, 29) ]; variations in the compounds and the doses employed did not produce appreciable differences in the results. As expected, there was a good correlation between the binding capacity of TBG, the T3 resin uptake test, and the PBI. The mean percentage distribution of T3 among the binding proteins showed 61.7%o bound to TBG, 31.5%o to albumin, and the rest to globulins cathodal to TBG. In our studies, performed at pH 8.6, no binding to TBPA was observed; this was in agreement with all previous observations (9-16).
In vivo. There was no appreciable difference between the 20-minute counts in the estrogen-treated patients and the control group in the T4 studies. However, the estrogen-treated patients studied with T4 had a mean T4 acute halftime of 150 minutes, which was significantly higher than control values (p < 0.01). The retention of T4 within the blood was also shown by the percentage radioactivity of the 20-minute count remaining in the circulation at 50 minutes (mean 87.2%). This is 12% more than the control values (p < 0.01) and 25% more than the results in the patients given DPH. The T3 acute half-time, on the other hand, had a mean of 76.1 minutes, which was not significantly different from the T3 control group or the T3 results in the patients taking DPH. The slopes derived by plotting on semilogarithmic paper the points between the 10 and 60 minutes are shown in Figure 1, Diphenylhydantoin (DPH) -treated (Table IV) The mean T3 acute half-time in these patients was 71. 3 T Normal values for this laboratory. § Mean of four determinations. 11 10% of the radioactivity was present in the area cathodal to albumin in the a-and 8-globulin areas.
PBI in the DPH group was 3.9 tug per 100 ml, whereas the mean T3 resin uptake test was 34.0%.
Patient ueith idiopathic lack of TBG (Table V) In vitro. In this patient (G.F.) the binding capacity of TBG was so low that it could not be determined even with very low concentrations of added stable T4; his blood was thus devoid of appreciable TBG. In the electrophoresis there was a greater percentage than normal of T4 in the TBPA zone. The in vitro addition of stable L-T4 in varying concentrations showed the hormone to be bound primarily to TBPA and secondarily to albumin. The binding capacity of TBPA averaged 173.3 jug per 100 ml in several determinations. Radioautographs of the electrophoretic distribution of T3 and T4 among the thyroxine-binding proteins in serum from this patient showed a total lack of radioactivity in the TBG area after distribution of T4. T4 was bound mainly by TBPA and T3 by albumin; there was a small amount of T3 radioactivity in the area cathodal to albumin. The T4 studies showed no trailing of radioactivity.
The serum free T4 found in this patient was 0.098%o of the total concentration of circulating thyroxine, which, as expected, was significantly higher than the normal control values in our laboratory (0.054%o). The serum free T3 was 0.69%o of the bound hormone, normal control value 0.61%o.
In vivo. The acute disappearance of T, was very rapid (half-time, 39 minutes), slightly faster than the values in the DPH-treated group. The 20-minute value for T4 was markedly reduced (to 9.2% of the standard) and approximated the Ta 20-minute value. However, the T3 acute halftime was 69 minutes, not significantly different from the normal control group. Discussion After intravenous injection, tracer amounts of L-T4 and L-T8 initially disappear rapidly from the blood to reach equilibrium in the body pool in 12 to 48 hours; subsequently the disappearance of the labeled hormone proceeds slowly in an exponential manner, and the slope so derived is considered to represent solely turnover of the injected hormone in a steady state (30, 31) . The binding of thyroxine to the plasma proteins has been demonstrated to be a factor in the regulation of the disappearance rate of T4 when followed for several days after injection. Thus, an increase in the thyroxine binding capacity of TBG is followed by a delay in the disappearance of thyroxine from the circulation (21) , and the opposite effect is seen after depression of the thyroxine binding capacity of TBG (6) . Similar effects on the turnover of T, have also been observed in patients with familial overproduction of TBG (32, 33) and in those with lack of TBG (26, 34, 35) . It has also been shown that TBPA plays an important role in the turnover of T4 under certain circumstances (23) . Observations in hyperthyroid and hypothyroid patients (30, 36, 37) suggested that the metabolic rate also appears to be a factor in the disappearance of thyroxine in this later slow phase.
By studying the first 50 minutes after injection of the labeled hormone ("acute disappearance") we eliminated the metabolic factor, since degradation is insignificant during the 30-minute period utilized to derive a slope. Furthermore, previous studies in our laboratory have shown that this phase is unaffected by changes in the metabolic rate or of blood flow: Thus the increased metabolic rate of malignant disease, or that induced by warming the body in a bath (which also increases blood flow), had no effect on acute disappearance rates (38) . We felt that this early and rapid phase of T3 or T4 disappearance might be dependent at least in large part on binding properties in the circulation and could be studied in the absence of other factors attendant on the later phase of dynamic equilibrium.
By 20 minutes after injection, the disappearance of T3 from the circulation was much greater than that of T4, although the subsequent 20-to 50-minute slopes of T, and T4 disappearance were similar in the control group. The explanation of this rapid 20-minute loss of T3 is not clear, although it is related to an increased distribution space for T3, which may be readily calculated from the 20-minute counts and the standard counts.
Presumably the T3 diffuses very rapidly into this initial volume of distribution within the first few minutes. After that diffusion, which is virtually completed by 10 minutes (see Figure 1) , any short part of the curve (capable of analysis) may be arbitrarily chosen for study, at least until the time that cellular metabolism becomes a significant factor. Results do not differ qualitatively when any part of the curve between 10 and 90 minutes is analyzed (39) , although there are then more variables and even more problems in analysis of the data. Furthermore, the 20-to 50-minute interval was found to give the best statistical separation (for the T4 studies) among the various groups studied. Hence it seems justifiable to arbitrarily pick the 20-to 50-minute interval for analysis of acute disappearance for both hormones. It must nevertheless be conceded that the 20-to 50-minute period is possibly more sensitive to measurements of the rate of egress of T4 from the vascular compartment than to measurements of the rate of egress of T3.
The larger initial volume of distribution for T3 is very likely related to binding properties. The explanation for the lower 20-minute values for T3 (as compared to T4), while the 20-to 50-minute slopes are so similar, is not known with certainty. One might speculate that the role of the specific protein TBG may be important in this regard, since the initial volume of distribution for T4 can be enlarged by decreasing TBG. It may be that TBG acts very rapidly to bind T4, thus reducing its initial volume of distribution; the binding of T3 to presumably nonspecific binding sites may be somewhat slower, thus permitting a wider initial volume of distribution. However, by the end of the first 10 minutes, this phase would appear to be virtually complete in each instance, thus allowing a comparison of later parts of the curve. This hypothesis is given credence by the observation that in the absence of TBG (Table V) , the 20-minute count for T4 approaches that for T3, and the volumes of distribution for T4 and T3 are thus similar under these circumstances. Furthermore, these data are similar to observations made by Brown-Grant and Tata (40) in rabbits. These authors found a much larger volume of distribution for T3 (compared to T4) within 5 minutes after injection and correlated these observations with the binding affinities of both hormones for TBG (which in rabbits are similar to man).
It is evident that the volume of distribution at 10 or 20 minutes is comprised of the blood volume plus a variable amount of extravascular space. Although a reduction in TBG appeared to cause a larger volume of distribution for T4 (as represented by lower 20-minute counts), an increase in TBG (e.g., with estrogen treatment) caused no significant decrease in the initial volume of T4 distribution. A possible reason for this apparent inconsistency may be that the blood volume represents the irreducible minimum for the initial volume of distribution. The mean volume of distribution at 20 minutes for the T4 studies was 6.87 L for the normal control group. This value is not much greater than the blood volume and presumably could not be appreciably contracted by increasing TBG.
In the T4 studies, alterations induced in TBG binding of T4 caused predictable changes in T4 acute disappearance in the 20-to 50-minute interval. Thus the presence of increased unsaturated TBG binding capacity (estrogen therapy, myxedema) was associated with a marked decrease in the T4 acute disappearance rates [as previously demonstrated (25) ], whereas reduced unsaturated TBG binding capacity (DPH treatment, idiopathic lack of TBG, hyperthyroidism) was accompanied by acceleration of the T4 acute disappearance rates.
By contrast, T3 acute disappearance rates were not significantly altered from control values by either an increased or decreased TBG binding capacity. This observation differed from the in vitro findings, in which T3 binds to TBG (albeit less strongly than T4); furthermore in these in vitro studies, increased available TBG binding capacity resulted in increased TBG binding of T3, and vice versa.
In patients with liver disease, preliminary observations (39) confirm the marked delay in T4 acute disappearance rates similar to those found by Lennon, Engbring, and Engstrom (24) . However, contrary to the estrogen results, there was no significant increase in TBG binding capacity in the liver disease group (39) . Early data from our laboratory suggest that a delay in the handling of T4 by the liver in this group may be a major factor in the slowing of the T4 acute disappearance rates as previously observed (41) . In any event, the T3 acute disappearance values were again unchanged from control values.
It therefore seems evident that changes in TBG binding capacity exert a profound effect on T acute disappearance, but no appreciable effect on T3 acute disappearance rates. Thus T3 is apparently not bound to TBG in vivo. An alternative explanation might be that there is TBG binding of T3 in vivo, but of such a minor magnitude that significant changes in T3 acute disappearance can--not be detected after alterations in TBG capacity. The fact that in the T3 studies the lowest 20-minute value was found in the patient with lack of TBG suggests that TBG may possibly play a minor role in at least the initial phase of T3 transport. It 
Summary
The acute half-time of disappearance of 131IJ labeled 3,5,3'-L-triiodothyronine (T3) from the circulation between 20 and 50 minutes after intravenous injection was determined in normal persons, in patients with thyroid disease, in patients with hepatic cirrhosis, in subjects given either diphenylhydantoin sodium or estrogens, and in one person with idiopathic lack of TBG. In some of these patients the same study was done with L-thyroxine (T4). The thyroxine binding capacity of thyroxine-binding globulin (TBG) was determined by filter paper electrophoresis in Trismaleate buffer (pH 8.6). It was found that labeled T3 half-time is not significantly shorter than labeled T4 half-time and, unlike the latter, shows no significant variation among euthyroid, hyperthyroid, myxedematous, and cirrhotic patients and those lacking TBG. The labeled T4 half-time markedly decreased after intravenous administration of diphenylhydantoin; by contrast, no significant effect was observed in labeled T3 half-time under the same circumstances. Findings similar to the diphenylhydantoin results were obtained in the patient with idiopathic lack of TBG. In the estrogen-treated group, labeled T4 half-time increased to values twice the control. In these patients also, no significant changes were seen in the labeled T3 half-time; however, the in vitro binding of radioactive T3 by TBG in sera of patients in this group showed a significant increase, as revealed by electrophoresis and by the labeled T3 resin uptake test. It therefore appears that there is virtually no in vivo binding of T3 by TBG; alternatively, if there is T3-TBG binding in vivo, it must be of such minor magnitude that it cannot be demonstrated by acute disappearance studies.
